Indaptus Therapeutics, Inc.
- INDP
- NASDAQ
- Biotechnology
- Immunotherapy
- Preclinical Biotech
- Cancer/Viral Therapeutics
$2.73
Today +3.80%Quote Oct 19, 2026, 08:00 PM UTC
−33.08%over the last month
Max drawdown −47.0%From 1-month high −34.3%3 months +6.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Indaptus Therapeutics
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
5
Founded
2021
Market value
$363.8M
Quote Oct 19
Floor
$2.68
1.7% below price
Resistance
$2.86
4.6% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about INDPPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free